TRODELVY® (sacituzumab govitecan-hziy) is a prescription medicine used to treat adults with hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to other parts of the body (metastatic) or cannot be removed by surgery, and who previously received endocrine therapy and at least two additional treatments for metastatic disease. It is not known if TRODELVY is safe and effective in people with moderate or severe liver problems or in children.

HR+/HER2- Metastatic Breast Cancer
A Black woman in her mid-40s with short natural hair is sitting at her kitchen table at breakfast time with her partner, a Black man in his mid-40s, and 2 sons, aged 4 and 13. Both boys are in their pajamas, and the younger boy is kneeling up on his chair, talking excitedly. The woman is looking at him and smiling. Not actual patients.

FINANCIAL ACCESS AND SUPPORT

TRODELVY ACCESS SUPPORT assists patients with insurance questions regarding benefits and coverage, and offers financial support guidance, including out-of-pocket cost assessments and alternate assistance options.

TRODELVY Access Support Logo.

For additional information, contact a TRODELVY ACCESS SUPPORT Case Manager.

Monday-Friday, 9 AM-7 PM EST at 1-844-TRODELVY (1-844-876-3358).

Choose a tab to learn more about the financial support options that may be available to you based on your insurance type.

TRODELVY Savings Program card.

About the TRODELVY Savings Program

If you are commercially or privately insured, the TRODELVY Savings Program* offers you savings on out-of-pocket expenses of TRODELVY 180-mg single-dose vials, up to $25,000 annually.

Terms and conditions apply.†

  • Patients may pay as little as $0 out-of-pocket for TRODELVY, which includes co-pay and coinsurance, up to $25,000 annually
  • The Program only assists with cost of TRODELVY; patient is responsible for cost-share of treatments and office visits
  • This Program does not support any claims covered, paid, or reimbursed, in whole or in part, by Medicaid, Medicare, or other federal or state healthcare programs

How the Program Works

Your healthcare provider's office or TRODELVY ACCESS SUPPORT can help you apply.

Download the TRODELVY ACCESS SUPPORT Enrollment Form and then talk to your healthcare provider about the enrollment process:

  • Your healthcare provider purchases and administers TRODELVY
  • Your healthcare provider submits a claim to your insurance plan
  • You and your healthcare provider will receive an Explanation of Benefits, which shows how much your healthcare provider was reimbursed and how much you owe for the cost of TRODELVY
  • If approved, you or your healthcare provider will be reimbursed up to $25,000 annually by the TRODELVY Savings Program. Your healthcare provider may collect any remaining balance from you

*The TRODELVY Savings Program is not available to patients with any form of government insurance. Patients must meet certain eligibility criteria to qualify for this program. Once enrolled, the patient may pay $0 out-of-pocket for TRODELVY with maximum benefit of $25,000 per year.

†Click here to view the Terms & Conditions.

Independent Foundation Assistance*

If you have government insurance, like Medicare, Medicaid, or VA, you will have access to TRODELVY ACCESS SUPPORT Case Managers who can provide you with information about third-party organizations that may be able to help with co-pays, deductibles, and insurance premiums related to your TRODELVY treatment.

If you have questions, call a TRODELVY ACCESS SUPPORT Case Manager at 1-844-TRODELVY (1-844-876-3358).

*Patients with Medicare or other government insurance who need assistance with cost-share requirements for TRODELVY may be eligible for co-pay or coinsurance assistance through an independent co-pay assistance foundation. Case managers can help patients assess their high-level eligibility for possible coverage for TRODELVY through an independent co-pay assistance foundation. If co-pay assistance needs are identified, the case managers can provide information about any available foundations. The foundation will determine the patient's eligibility for co-pay or coinsurance assistance based on their own criteria, completely independent of Gilead and its agents, and will contact the patient directly regarding the application process. Gilead and its agents make no guarantee regarding reimbursement for any service or item.

Gilead Patient Assistance Program*

Eligible patients who are uninsured can receive TRODELVY at no cost with help from the Gilead PAP.

To determine if you are eligible for the program, your healthcare provider will

  • Provide you with an application to complete and sign
  • Submit your completed application to TRODELVY ACCESS SUPPORT
  • Notify you if you are eligible

If you have questions, call a TRODELVY ACCESS SUPPORT Case Manager at 1-844-TRODELVY (1-844-876-3358).

*Gilead PAP provides TRODELVY free of charge for eligible patients who are uninsured. To qualify for assistance, patients must meet certain eligibility criteria.

TRODELVY support may vary based on application criteria and is subject to change or discontinuation. Prior authorizations and appeals must be submitted by a physician’s office.

Start Your Enrollment

CURIOUS IF YOU’RE ELIGIBLE FOR SAVINGS?

Once you have a prescription, download the TRODELVY ACCESS SUPPORT Enrollment Form to complete the process with your healthcare provider.

arrow_upward Back to Top

What is TRODELVY?

TRODELVY® (sacituzumab govitecan-hziy) is a prescription medicine used to treat adults with hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to other parts of the body (metastatic) or cannot be removed by surgery, and who previously received endocrine therapy and at least two additional treatments for metastatic disease.

It is not known if TRODELVY is safe and effective in people with moderate or severe liver problems or in children.

Important Safety Information

TRODELVY can cause serious side effects, including low white blood cell count and diarrhea:

Tap for Important Safety Information. TRODELVY can cause serious side effects, including low white blood cell count and diarrhea:

  • Low white blood cell count (neutropenia) which is common and can sometimes be severe and lead to infections that can be life-threatening or cause death. Your healthcare provider should check your blood cell counts during treatment. If your white blood cell count is too low, your healthcare provider may need to lower your dose, give you a medicine to help prevent low blood cell count with future doses of TRODELVY, or in some cases may stop TRODELVY. Your healthcare provider may need to give you antibiotic medicines if you develop fever while your white blood cell count is low. Call your healthcare provider right away if you develop any of the following signs of infection: fever, chills, cough, shortness of breath, or burning or pain when you urinate.
  • Severe diarrhea. Diarrhea is common and can be severe. Severe diarrhea can lead to loss of too much body fluid (dehydration) and kidney problems. Your healthcare provider should monitor you for diarrhea and give you medicine as needed to help control it. If you lose too much body fluid, your healthcare provider may need to give you fluids and electrolytes to replace body salts. If you develop diarrhea during your treatment with TRODELVY, your healthcare provider should check to see if it may be caused by an infection. Your healthcare provider may decrease your dose or stop TRODELVY if your diarrhea is severe and cannot be controlled with anti-diarrheal medicines.
    • Call your healthcare provider right away the first time that you get diarrhea during treatment with TRODELVY; if you have black or bloody stools; if you have symptoms of dehydration, such as lightheadedness, dizziness, or faintness; if you are unable to take fluids by mouth due to nausea or vomiting; or if you are not able to get your diarrhea under control within 24 hours.

Do not receive TRODELVY if you have had a severe allergic reaction to TRODELVY. Ask your healthcare provider if you are not sure.

Allergic and infusion-related reactions which can be serious and life-threatening. Tell your healthcare provider or nurse right away if you get any of the following symptoms during your infusion of TRODELVY or within 24 hours after: swelling of your face, lips, tongue, or throat; hives; skin rash, itching, or flushing of your skin; fever; difficulty breathing or wheezing; lightheadedness, dizziness, feeling faint, or pass out; or chills or shaking chills (rigors).

Nausea and vomiting are common with TRODELVY and can sometimes be severe. Before each dose of TRODELVY, you will receive medicines to help prevent nausea and vomiting along with medicines to take home with instructions about how to take them. Call your healthcare provider right away if you have nausea or vomiting that is not controlled with the medicines prescribed for you. Your healthcare provider may decide to decrease your dose or stop TRODELVY if your nausea and vomiting is severe and cannot be controlled with anti-nausea medicines.

Before receiving TRODELVY, tell your healthcare provider about all of your medical conditions, including if you:

  • have been told that you carry a gene for UGT1A1*28, which can increase your risk of getting side effects with TRODELVY, especially low white blood cell counts, with or without a fever, and low red blood cell counts.
  • have liver problems.
  • are pregnant or plan to become pregnant. TRODELVY can harm your unborn baby. Your healthcare provider should check to see if you are pregnant before you start receiving TRODELVY. TRODELVY may cause fertility problems in females, which could affect your ability to have a baby. Talk to your healthcare provider if fertility is a concern for you.
    • Females who can become pregnant should use effective birth control during treatment and for 6 months after your last dose of TRODELVY. Talk to your healthcare provider about birth control choices that may be right for you during this time. Tell your healthcare provider right away if you become pregnant during treatment with TRODELVY.
    • Males with a female partner who can become pregnant should use effective birth control during treatment and for 3 months after your last dose of TRODELVY.
  • are breastfeeding or plan to breastfeed. It is not known if TRODELVY passes into your breastmilk and can harm your baby. Do not breastfeed during treatment and for 1 month after your last dose of TRODELVY.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Certain medicines may affect the way TRODELVY works.

The most common side effects of TRODELVY include decreased white blood cell (leukocyte and lymphocyte) and red blood cell counts, feeling tired or weak, hair loss, constipation, increased sugar levels in the blood, decreased protein levels (albumin) in the blood, decreased appetite, changes in kidney function test, increased levels of enzyme called alkaline phosphatase in the blood (test for liver or bone problems), and decreased levels of magnesium, potassium, and sodium in the blood.

These are not all of the possible side effects of TRODELVY. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please click to see Important Facts about TRODELVY, including Important Warning.